TCR-α/β and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience

References

• Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol. 1992;10(11):1690–1695. doi:10.1200/JCO.1992.10.11.1690
   PubMed Web of Science ®Google Scholar
• Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131(2):223–230. doi:10.1111/j.1365-2141.2005.05755.x
   PubMed Web of Science ®Google Scholar
• Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1997;20(5):369–374. doi:10.1038/sj.bmt.1700904
   PubMed Web of Science ®Google Scholar
• van Besien K, Thall P, Korbling M, et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin’s lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997;3(3):150–156.
   PubMedGoogle Scholar
• Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Blood. 1994;84(4):1050–1055. doi:10.1182/blood.V84.4.1050.1050
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18):3671–3677. doi:10.1182/blood-2009-12-253856
   PubMed Web of Science ®Google Scholar
• Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455–462. doi:10.1200/JCO.2007.13.2415
   PubMed Web of Science ®Google Scholar
• Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934–1941. doi:10.1016/S0140-6736(05)66659-7
   PubMed Web of Science ®Google Scholar
• Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12(2):172–183. doi:10.1016/j.bbmt.2005.09.009
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98(13):3595–3599. doi:10.1182/blood.v98.13.3595
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16(8):2817–2824. doi:10.1200/JCO.1998.16.8.2817
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(12):1326–1334. doi:10.1016/j.bbmt.2006.08.035
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(2):211–217. doi:10.1200/JCO.2007.11.5477
   PubMed Web of Science ®Google Scholar
• Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111(12):5530–5536. doi:10.1182/blood-2008-01-136242
   PubMed Web of Science ®Google Scholar
• Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):79–91. doi:10.1016/0198-8859(90)90071-v
   PubMed Web of Science ®Google Scholar
• Beetz S, Marischen L, Kabelitz D, et al. Human gamma Delta T cells: candidates for the development of immunotherapeutic strategies. Immunol Res. 2007;37(2):97–111. doi:10.1007/BF02685893
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Bluestone JA, et al. Murine gamma/Delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens. Blood. 1996;87(10):4463–4472. doi:10.1182/blood.V87.10.4463.bloodjournal87104463
   PubMed Web of Science ®Google Scholar
• Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18(5):539–546. doi:10.1016/j.coi.2006.07.002
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Majewski D, Hanson G. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5(4):222–230. doi:10.1053/bbmt.1999.v5.pm10465102
   PubMedGoogle Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304. doi:10.1097/00007890-197410000-00001
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Cornish J, Labopin M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010;115(17):3437–3446. doi:10.1182/blood-2009-03-207001
   PubMed Web of Science ®Google Scholar
• Viey E, Fromont G, Escudier B, et al. Phosphostim-activated gamma Delta T cells kill autologous metastatic renal cell carcinoma. J Immunol. 2005;174(3):1338–1347. doi:10.4049/jimmunol.174.3.1338
   PubMed Web of Science ®Google Scholar
• Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122(8):1510–1517. doi:10.1182/blood-2013-04-495895
   PubMed Web of Science ®Google Scholar
• Michallet M, Socie G, Mohty M, et al. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. Exp Hematol. 2013;41(2):127–133. doi:10.1016/j.exphem.2012.10.008
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Lang P, Feuchtinger TF, et al. Transplantation of TcRab/CD19 Depleted Stem Cells From Haploidentical Donors: Robust Engraftment and Rapid Immune Reconstitution In Children with High Risk Leukemia. Blood. 2011;118(21):1005
   Google Scholar
• Schumm M, Bethge LP, Vogel W, et al. Depletion of TcRab + and CD19-positive cells from leukapheresis products with the CliniMACS device. In: BMT Tandem Meetings, Honolulu, Hawaii; 2011. p. S339–S340.
   Google Scholar
• Chang H-M, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2017;70(20):2536–2551. doi:10.1016/j.jacc.2017.09.1096
   PubMedGoogle Scholar
• Klaus R, Niyazi M, Lange-Sperandio B. Radiation-induced kidney toxicity: molecular and cellular pathogenesis. Radiat Oncol. 2021;16(1):43. doi:10.1186/s13014-021-01764-y
   PubMed Web of Science ®Google Scholar
• Hanna GG, Murray L, Patel R, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol (R Coll Radiol). 2018;30(1):5–14. doi:10.1016/j.clon.2017.09.007
   PubMedGoogle Scholar
• Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant. 2021;56(8):1805–1817. doi:10.1038/s41409-021-01283-0
   PubMed Web of Science ®Google Scholar
• Postalcioglu M, Kim HT, Obut F, et al. Impact of thrombotic microangiopathy on renal outcomes and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(11):2344–2353. doi:10.1016/j.bbmt.2018.05.010
   PubMed Web of Science ®Google Scholar
• Holtan S, Hamadani M, Wu J, et al. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft versus host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703. ASH meeting 2022, Abstract LBA-4. doi:10.1182/blood-2022-171463
   Google Scholar